Controlled nanoliposome formation with EncapX®
16 February 2026
A recent dynamic light scattering characterisation of nanoliposomes produced with EncapX® shows a main intensity peak at 93.3 nm and a PDI of 0.151. The sample is a single unimodal population.
The distribution has a defined peak and no detectable secondary population. A PDI around 0.15 indicates a narrow size distribution, which matters for reproducibility, colloidal stability and predictable biological performance.
EncapX® is described as enabling controlled formation of lipid-based nanoparticles under scalable processing conditions. Compatibility has already been shown with several active compounds, including RNA systems (mRNA, siRNA, antisense RNA) and other pharmaceutical actives. The same note says the scope continues to widen across cosmetic and advanced lipid nanoparticle platforms.
Related news
Talk at EMSF 2026, the European Meeting on Supercritical Fluids
Continuous supercritical CO₂ fractionation of wet microalgal suspensions for selective recovery of neutral lipids, by Elissandro Klein.
26 June 2026 · Clausthal-Zellerfeld, Germany
A patented continuous process to fractionate microalgae
A patented continuous process fractionates microalgae with supercritical CO₂ and without a drying step, to recover compounds such as omega-3.
18 July 2024
Biotech One pitches EncapX® to France BioLead members
An exclusive member session on 6 November, on bridging R&D formulation and industrial bioproduction for liposome and LNP manufacturing.
5 November 2026